AptarGroup, Inc.
ATR Healthcare Medical Instruments & Supplies
AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024.
- Revenue
- +6.03%
- EPS
- −73.9%
- Free cash flow
- −16.9%
- Total debt
- +14.6%
Quarter to September 2026, against a year earlier
Follow ATR
Alert me
AptarGroup, Inc. (ATR) EV/Sales
As of 5 November 2026, AptarGroup, Inc. (ATR) trades at a EV/Sales of 2.6×. Over the past ten years it has ranged from 1.6× (January 2015) to 3.7× (May 2021); the current reading is higher than 49% of that period. That is below the Medical Instruments & Supplies industry median of 2.8× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | (23.15%) |
| FY2024 | 3.1× | 22.77% |
| FY2023 | 2.6× | 2.84% |
| FY2022 | 2.5× | (10.73%) |
| FY2021 | 2.8× | (15.54%) |
| FY2020 | 3.3× | 13.92% |
| FY2019 | 2.9× | 17.43% |
| FY2018 | 2.5× | 1.69% |
| FY2017 | 2.4× | 15.13% |
| FY2016 | 2.1× | 0.58% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.2× | (4.45%) |
| Jun 2026 | 2.3× | (2.29%) |
| Mar 2026 | 2.4× | (1.22%) |
| Dec 2025 | 2.4× | (9.30%) |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BAX Baxter International Inc. compare | 1.7× |
| AVTR Avantor, Inc. compare | 2.0× |
| BLCO Bausch + Lomb Corporation compare | 2.2× |
| SOLV Solventum Corporation compare | 2.4× |
| ALGN Align Technology, Inc. compare | 2.4× |
| ATR AptarGroup, Inc. | 2.6× |
| COO The Cooper Companies, Inc. compare | 3.5× |
| TFX Teleflex Incorporated compare | 4.1× |
| RGEN Repligen Corporation compare | 11.6× |
| Medical Instruments & Supplies industry median | 2.8× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on ATR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement